Overview

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.

Phase:

Phase 2

Details

Lead Sponsor:

Accelerated Community Oncology Research Network

Collaborators:

AstraZeneca
Hoffmann-La Roche

Treatments:

Capecitabine
Estradiol
Fulvestrant
Hormones